Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 137.42
FLML's Cash to Debt is ranked higher than
54% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. FLML: 137.42 )
Ranked among companies with meaningful Cash to Debt only.
FLML' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 12.70 Max: N/A
Current: 137.42
Equity to Asset 0.27
FLML's Equity to Asset is ranked lower than
85% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. FLML: 0.27 )
Ranked among companies with meaningful Equity to Asset only.
FLML' s Equity to Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.53 Max: 0.8
Current: 0.27
-0.13
0.8
Interest Coverage 8.79
FLML's Interest Coverage is ranked lower than
82% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. FLML: 8.79 )
Ranked among companies with meaningful Interest Coverage only.
FLML' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 8.79
F-Score: 9
Z-Score: 1.78
M-Score: 0.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 37.79
FLML's Operating margin (%) is ranked higher than
93% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. FLML: 37.79 )
Ranked among companies with meaningful Operating margin (%) only.
FLML' s Operating margin (%) Range Over the Past 10 Years
Min: -635.24  Med: -81.82 Max: -26.53
Current: 37.79
-635.24
-26.53
Net-margin (%) 12.81
FLML's Net-margin (%) is ranked higher than
82% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. FLML: 12.81 )
Ranked among companies with meaningful Net-margin (%) only.
FLML' s Net-margin (%) Range Over the Past 10 Years
Min: -574.66  Med: -67.12 Max: -12.37
Current: 12.81
-574.66
-12.37
ROE (%) 65.25
FLML's ROE (%) is ranked higher than
98% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. FLML: 65.25 )
Ranked among companies with meaningful ROE (%) only.
FLML' s ROE (%) Range Over the Past 10 Years
Min: -1103.89  Med: -26.74 Max: -10.71
Current: 65.25
-1103.89
-10.71
ROA (%) 13.43
FLML's ROA (%) is ranked higher than
93% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. FLML: 13.43 )
Ranked among companies with meaningful ROA (%) only.
FLML' s ROA (%) Range Over the Past 10 Years
Min: -58.46  Med: -16.40 Max: -3.46
Current: 13.43
-58.46
-3.46
ROC (Joel Greenblatt) (%) 3056.75
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. FLML: 3056.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLML' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -662.22  Med: -93.16 Max: -36.66
Current: 3056.75
-662.22
-36.66
Revenue Growth (3Y)(%) -32.40
FLML's Revenue Growth (3Y)(%) is ranked lower than
79% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. FLML: -32.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLML' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.4  Med: -1.20 Max: 42.8
Current: -32.4
-32.4
42.8
EBITDA Growth (3Y)(%) 106.80
FLML's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. FLML: 106.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FLML' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.7  Med: -22.50 Max: 122.3
Current: 106.8
-50.7
122.3
EPS Growth (3Y)(%) 90.20
FLML's EPS Growth (3Y)(%) is ranked higher than
97% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. FLML: 90.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FLML' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.4  Med: -17.95 Max: 95.8
Current: 90.2
-38.4
95.8
» FLML's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

FLML Guru Trades in Q1 2015

Steven Cohen 355,800 sh (New)
» More
Q2 2015

FLML Guru Trades in Q2 2015

Steven Cohen Sold Out
» More
Q4 2015

FLML Guru Trades in Q4 2015

Steven Cohen 67,012 sh (New)
» More
Q1 2016

FLML Guru Trades in Q1 2016

Steven Cohen 358,958 sh (+435.66%)
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SGMO, NAS:GALE, NAS:CYAD, NAS:OMER, OTCPK:ZLDPF, NAS:RVNC, NAS:AMRN, NAS:GERN, NAS:ACRS, NAS:ESPR, NAS:OMED, NAS:OCAT, NAS:CYTK, NAS:TLGT, NAS:ENTA, NAS:CTMX, NAS:MYOK, NAS:CLDX, NAS:ASND, NAS:NDRM » details
Traded in other countries:FL3.Germany,
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in drug delivery and formulation to develop safer and more efficacious pharmaceutical products to address unmet medical needs and reduce overall healthcare costs.

Flamel Technologies SA was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.

Ratios

vs
industry
vs
history
P/E(ttm) 89.47
FLML's P/E(ttm) is ranked lower than
77% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. FLML: 89.47 )
Ranked among companies with meaningful P/E(ttm) only.
FLML' s P/E(ttm) Range Over the Past 10 Years
Min: 16.82  Med: 79.37 Max: 100.42
Current: 89.47
16.82
100.42
Forward P/E 135.14
FLML's Forward P/E is ranked lower than
91% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. FLML: 135.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 89.47
FLML's PE(NRI) is ranked lower than
77% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. FLML: 89.47 )
Ranked among companies with meaningful PE(NRI) only.
FLML' s PE(NRI) Range Over the Past 10 Years
Min: 16.76  Med: 78.05 Max: 98.75
Current: 89.47
16.76
98.75
Price/Owner Earnings (ttm) 17.97
FLML's Price/Owner Earnings (ttm) is ranked higher than
73% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 32.52 vs. FLML: 17.97 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
FLML' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.3  Med: 136.84 Max: 537.22
Current: 17.97
8.3
537.22
P/B 6.23
FLML's P/B is ranked lower than
68% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. FLML: 6.23 )
Ranked among companies with meaningful P/B only.
FLML' s P/B Range Over the Past 10 Years
Min: 1.84  Med: 4.95 Max: 71.87
Current: 6.23
1.84
71.87
P/S 2.53
FLML's P/S is ranked higher than
83% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. FLML: 2.53 )
Ranked among companies with meaningful P/S only.
FLML' s P/S Range Over the Past 10 Years
Min: 2.03  Med: 5.65 Max: 41.79
Current: 2.53
2.03
41.79
PFCF 12.32
FLML's PFCF is ranked higher than
82% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 26.54 vs. FLML: 12.32 )
Ranked among companies with meaningful PFCF only.
FLML' s PFCF Range Over the Past 10 Years
Min: 9.83  Med: 24.09 Max: 154.15
Current: 12.32
9.83
154.15
POCF 11.99
FLML's POCF is ranked higher than
78% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. FLML: 11.99 )
Ranked among companies with meaningful POCF only.
FLML' s POCF Range Over the Past 10 Years
Min: 9.66  Med: 21.47 Max: 51.48
Current: 11.99
9.66
51.48
EV-to-EBIT 4.44
FLML's EV-to-EBIT is ranked higher than
82% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. FLML: 4.44 )
Ranked among companies with meaningful EV-to-EBIT only.
FLML' s EV-to-EBIT Range Over the Past 10 Years
Min: -54.8  Med: -11.40 Max: 6
Current: 4.44
-54.8
6
EV-to-EBITDA 3.64
FLML's EV-to-EBITDA is ranked higher than
84% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. FLML: 3.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
FLML' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4256.2  Med: -15.00 Max: 1473.5
Current: 3.64
-4256.2
1473.5
PEG 1.20
FLML's PEG is ranked higher than
72% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. FLML: 1.20 )
Ranked among companies with meaningful PEG only.
FLML' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: N/A
Current: 1.2
Current Ratio 2.96
FLML's Current Ratio is ranked lower than
64% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. FLML: 2.96 )
Ranked among companies with meaningful Current Ratio only.
FLML' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 2.78 Max: 6.76
Current: 2.96
0.83
6.76
Quick Ratio 2.87
FLML's Quick Ratio is ranked lower than
61% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. FLML: 2.87 )
Ranked among companies with meaningful Quick Ratio only.
FLML' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 2.68 Max: 6.7
Current: 2.87
0.74
6.7
Days Inventory 129.40
FLML's Days Inventory is ranked lower than
51% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. FLML: 129.40 )
Ranked among companies with meaningful Days Inventory only.
FLML' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 86.59 Max: 565.95
Current: 129.4
51.05
565.95
Days Sales Outstanding 10.05
FLML's Days Sales Outstanding is ranked higher than
89% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. FLML: 10.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLML' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.95  Med: 74.39 Max: 100.9
Current: 10.05
39.95
100.9
Days Payable 552.03
FLML's Days Payable is ranked higher than
95% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. FLML: 552.03 )
Ranked among companies with meaningful Days Payable only.
FLML' s Days Payable Range Over the Past 10 Years
Min: 180.56  Med: 245.25 Max: 1661.94
Current: 552.03
180.56
1661.94

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.56
FLML's Price/Tangible Book is ranked lower than
93% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. FLML: 33.56 )
Ranked among companies with meaningful Price/Tangible Book only.
FLML' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.39  Med: 4.68 Max: 113.64
Current: 33.56
1.39
113.64
Price/Projected FCF 14.92
FLML's Price/Projected FCF is ranked lower than
78% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. FLML: 14.92 )
Ranked among companies with meaningful Price/Projected FCF only.
FLML' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.16  Med: 7.55 Max: 93.64
Current: 14.92
5.16
93.64
Price/Median PS Value 0.45
FLML's Price/Median PS Value is ranked higher than
85% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. FLML: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
FLML' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.02 Max: 6.64
Current: 0.45
0.26
6.64
Price/Graham Number 11.55
FLML's Price/Graham Number is ranked lower than
93% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 3.09 vs. FLML: 11.55 )
Ranked among companies with meaningful Price/Graham Number only.
FLML' s Price/Graham Number Range Over the Past 10 Years
Min: 1.93  Med: 3.97 Max: 11.87
Current: 11.55
1.93
11.87
Earnings Yield (Greenblatt) (%) 22.74
FLML's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. FLML: 22.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLML' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 16.6  Med: 24.80 Max: 33.6
Current: 22.74
16.6
33.6

More Statistics

Revenue (TTM) (Mil) $176.7
EPS (TTM) $ 0.12
Beta1.01
Short Percentage of Float1.29%
52-Week Range $7.56 - 26.09
Shares Outstanding (Mil)41.24

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 134 149 166
EPS ($) 0.08 0.45 0.70
EPS w/o NRI ($) 0.08 0.45 0.70
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for FLML

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Jun 16 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 07 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Jun 02 2016
Flamel Technologies to Present at Two Upcoming Investor Conferences Jun 01 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 27 2016
ETF’s with exposure to Flamel Technologies SA : May 19, 2016 May 19 2016
FLAMEL TECHNOLOGIES SA Financials May 19 2016
Flamel Technologies SA :FLML-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
FLAMEL TECHNOLOGIES SA Files SEC form 10-Q, Quarterly Report May 10 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 09 2016
Edited Transcript of FLML earnings conference call or presentation 9-May-16 2:00pm GMT May 09 2016
Flamel Technologies Reports First Quarter 2016 Results May 09 2016
Q1 2016 Flamel Technologies SA Earnings Release - Before Market Open May 09 2016
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML May 06 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... May 04 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 02 2016
Flamel Technologies to Report First Quarter 2016 Results May 02 2016
Flamel Technologies Receives FDA Approval of Akovaz(TM) May 02 2016
Flamel Technologies to Present at Upcoming Investor Conferences Apr 22 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Apr 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)